Form 8-K - Current report:
SEC Accession No. 0000950170-25-046839
Filing Date
2025-03-28
Accepted
2025-03-28 16:30:08
Documents
11
Period of Report
2025-03-27
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K prld-20250327.htm   iXBRL 8-K 49900
  Complete submission text file 0000950170-25-046839.txt   196287

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20250327.xsd EX-101.SCH 50257
13 EXTRACTED XBRL INSTANCE DOCUMENT prld-20250327_htm.xml XML 4721
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39527 | Film No.: 25786820
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)